Abstract: The present invention is directed to 4-cyclopentyl resorcinol monohydrate, its Form I polymorph, formulations containing at least one of these compounds, and their use to lighten skin.
Type:
Grant
Filed:
January 28, 2004
Date of Patent:
March 4, 2008
Assignee:
Warner-Lambert Company
Inventors:
Martin James Procter, William Thomas Gattrell
Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.
Type:
Grant
Filed:
March 13, 2006
Date of Patent:
February 5, 2008
Assignees:
Warner-Lambert Company LLC, Abgenix, Inc.
Inventors:
Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.
Type:
Application
Filed:
February 15, 2007
Publication date:
December 20, 2007
Applicant:
WARNER-LAMBERT COMPANY
Inventors:
David Dooley, Charles Taylor, Jr., Andrew Thorpe, Fong Wang, David Wustrow
Abstract: The present invention provides a stabilized pharmaceutical preparation of a 4-amino-3-substituted-butanoic acid derivative which can be obtained by incorporating an amino acid as a stabilizer.
Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.
Type:
Application
Filed:
March 19, 2007
Publication date:
November 29, 2007
Applicant:
WARNER-LAMBERT COMPANY LLC
Inventors:
David Dooley, Charles Taylor, Jr., Andrew Thorpe, Fong Wang, David Wustrow
Abstract: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
Type:
Application
Filed:
November 2, 2006
Publication date:
November 22, 2007
Applicant:
WARNER-LAMBERT COMPANY LLC
Inventors:
Howard Bockbrader, Yun Cho, Steven Diaz Santiago, Majid Mahjour, Thomas Reynolds, Pushpa Shao, Zezhi Shao, Jiansheng Wan
Abstract: The present invention relates to secreted soluble ?2?-2, ?2?-3 or ?2?-4 calcium channel subunit polypeptides and their preparation, corresponding nucleic acids, recombinant vectors and host cells, as well as screening assays using same.
Abstract: The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.
Type:
Grant
Filed:
June 24, 2004
Date of Patent:
September 25, 2007
Assignee:
Warner-Lambert Company, LLC
Inventors:
Shannon Leigh Black, Michael David Kaufman, Daniel Fred Ortwine, Mark Stephen Plummer, John Quin, III, Gordon William Rewcastle, Aurash B. Shahripour, Julie Ann Spicer, Christopher Emil Whitehead
Abstract: This invention relates to combinations of atomoxetine, and a 5HT1A receptor agonists, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from ADHD, related disorders, and other central nervous system diseases or disorders.
Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.
Type:
Application
Filed:
March 19, 2007
Publication date:
September 13, 2007
Applicant:
WARNER-LAMBERT COMPANY LLC
Inventors:
David Dooley, Charles Taylor, Jr., Andrew Thorpe, Fong Wang, David Wustrow
Abstract: The invention concerns compositions based on pullulan and a setting system for the use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard capsules. The composition preferably further contains a surfactant. By using aqueous solution of the inventive compositions, the hard pullulan capsules are produced by a conventional dipping moulding process under the same process condition range than conventional gelatine capsules.
Type:
Grant
Filed:
September 15, 2004
Date of Patent:
September 11, 2007
Assignee:
Warner-Lambert Company, LLC
Inventors:
Robert Scott, Dominique Cade, Xiongwei He
Abstract: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.
Type:
Application
Filed:
August 22, 2005
Publication date:
September 6, 2007
Applicant:
WARNER-LAMBERT COMPANY LLC
Inventors:
Stephen Barrett, Daniel Du, Lain-Yen Hu
Abstract: This invention relates to combinations, compositions, and methods using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component for preventing or treating osteoarthritis, preventing or inhibiting cartilage damage, preventing or treating rheumatoid arthritis, improving joint function, alleviating pain, and the like in a patient in need thereof.
Type:
Application
Filed:
April 23, 2007
Publication date:
August 30, 2007
Applicant:
WARNER-LAMBERT COMPANY
Inventors:
SUSAN BOVE, JOSEPH CORNICELLI, KENNETH KILGORE, Mark Kowala, DAVID NEIDEFFER, DRAGO SLISCOVIC
Abstract: The present invention relates to three novel genes and polypeptides derived therefrom encoding “?2?-C” and/or “?2?-D” proteins which exist as a subunit in many calcium channels. The invention also describes methods for using the novel gene and polypeptides in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, binding assays in connection with chemical databases, gene therapy.
Type:
Grant
Filed:
October 7, 1999
Date of Patent:
August 28, 2007
Assignee:
Warner Lambert Company
Inventors:
Margaret Ann Johns, Brian Moldover, James David Offord
Abstract: This invention relates to novel tetrazole and oxadiazalone ?-amino acids derivatives of the formula wherein G is wherein R1 through R4 are defined as in the specification, pharmaceutical compositions containing them and their use for the treatment of various central nervous system and other disorders. The cyclopropyl ?-amino acids derivatives of this invention exhibit activity as alpha2delta ligands (?2? ligands). Such compounds have affinity for the ?2? subunit of a calcium channel.
Type:
Grant
Filed:
March 8, 2004
Date of Patent:
July 31, 2007
Assignee:
Warner Lambert Company LLC
Inventors:
Nancy Sue Barta, Norman Lloyd Colbry, Raymond Hudack, Jr., Kristin Knapp Lin, Jacob Bradley Schwarz, Andrew John Thorpe, David Juergen Wustrow, Zhijian Zhu
Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
Type:
Grant
Filed:
February 6, 2004
Date of Patent:
July 17, 2007
Assignee:
Warner Lambert Company LLC
Inventors:
Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
Inventors:
Cristina E. Bonaldes, Charles D. Denton, Heath A. Doty, Bryan Holmes, Marc Hunter, Victoria Noble, Randal D. Porter, Kim Sines, John E. Smethers, Russell Wright
Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
Type:
Grant
Filed:
November 28, 2005
Date of Patent:
November 6, 2007
Assignee:
Warner Lambert Company
Inventors:
Bruce J. Auerbach, Larry D. Bratton, Gary Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst